{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:59:08Z","timestamp":1780819148089,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcyt.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:54:45Z","timestamp":1762210485000},"page":"101997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A FOXP3+ cell-rich microenvironment associates with better overall survival after CAR-T cell therapy in relapsed\/refractory B-cell lymphoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-2905","authenticated-orcid":false,"given":"Simone","family":"Zanella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-6490","authenticated-orcid":false,"given":"Cristina","family":"Zucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-997X","authenticated-orcid":false,"given":"Chiara","family":"de Philippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-6896","authenticated-orcid":false,"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Bonometti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.10.007_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0006","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jcyt.2025.10.007_bib0007","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0010","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0011","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0012","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0013","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0014","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s00432-020-03398-1","article-title":"Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis","volume":"146","author":"Peng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0015","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: a review","volume":"234","author":"Najafi","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0018","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0019","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","article-title":"FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis","volume":"13","author":"Kobayashi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0625.2011.01260.x","article-title":"Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma","volume":"20","author":"Knol","year":"2011","journal-title":"Exp Dermatol"},{"issue":"18","key":"10.1016\/j.jcyt.2025.10.007_bib0021","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","article-title":"Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions","volume":"12","author":"Hiraoka","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer","volume":"27","author":"Salama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0023","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0025","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"\u00c1lvaro","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0026","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190701824536","article-title":"Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis","volume":"49","author":"Lee","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0028","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2014.110189","article-title":"Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP","volume":"100","author":"Coutinho","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0029","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/10428190902785528","article-title":"Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma","volume":"50","author":"S\u00e1ez","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2025.101635","article-title":"Tumor microenvironment in CAR-T cell therapy for lymphoma","volume":"38","author":"Zhu","year":"2025","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0031","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0032","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0033","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0034","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ejh.14103","article-title":"Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma","volume":"112","author":"Cai","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943354","article-title":"Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies","volume":"13","author":"Maharaj","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2025.10.007_bib0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gpb.2019.03.002","article-title":"Single-cell analysis of CAR-T cell activation reveals a mixed TH1\/TH2 response independent of differentiation","volume":"17","author":"Xhangolli","year":"2019","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0038","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0039","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-\u03b3 drives Treg fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.10.007_bib0041","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2016000885","article-title":"Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified","volume":"1","author":"Nakayama","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.jcyt.2025.10.007_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:19:41Z","timestamp":1780816781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1465324925008746"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.10.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A FOXP3+ cell-rich microenvironment associates with better overall survival after CAR-T cell therapy in relapsed\/refractory B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101997"}}